Cefotaxime in the treatment of septicaemia and endocarditis

Armengaud, M.; Massip, Patrice; Aubertin, J; Ragnaud, JM; Bertrand, A; Lepeu, G.

doi:10.1093/jac/6.suppl_a.263

Cited by 8 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ασθενών, μέ ουρολοιμώξεις(16), πνευμονία(9), λοιμώξεις μαλακών μορίων(12), οστεομυελίτιδα (3), σηψαιμία (5) καί αρθρίτιδα(2). Όλοι άνταποκρίθησαν εύνοϊκώς στή μοξαλακτάμη ένώ εις 36 (76%) επιπρο σθέτως έξαλείφθησαν καί τά παθογόνα .μικροβιακά στελέχη.…”

unclassified

Μοξαλακταμη. Μια Νεα Αντιψευδομοναδικη Ευρεως Φασματος Οξυ-Β-Λακταμη. Κλινικη Εργαστηριακη Και Φαρμακοκινητικη Μελετη

Τσαγκαρακησ¹

View full text Add to dashboard Cite

, vs gentamicin and cefotaxime in chronic urinary tract infections. Άνεκοινώθη εις τό 12ov Διεθνές Συνέδριον Χημειοθεραπείας εις Φλωρεντίαν. Ιούλιος 1981.' Αντιμικροβιακή δρασις ΤΙΚΑΡΚΙΛΛΙΝΗ Χημική σύνθεσις-ΤύποςΉ τικαρκιλλίνη συνετέθη εις τά χημικά εργαστήρια της Beecham τό 1966. Ό χημικός τύπος (a-carboxyl-3thienylmethyl penicillin) ομοιάζει πολύ μέ εκείνο της καρμπενικιλλίνης, διαφέρει μόνον εις μίαν πλαγίαν αλυσον.

show abstract

unclassified

Μοξαλακταμη. Μια Νεα Αντιψευδομοναδικη Ευρεως Φασματος Οξυ-Β-Λακταμη. Κλινικη Εργαστηριακη Και Φαρμακοκινητικη Μελετη

Τσαγκαρακησ¹

View full text Add to dashboard Cite

show abstract

The Third-Generation Cephalosporins

Gleckman¹,

Gantz²

1982

Arch Intern Med

View full text Add to dashboard Cite

Mechanism of Action, Antimicrobial Activity, Pharmacology, Adverse Effects, and Clinical Efficacy of Cefotaxime

LeFrock¹,

Prince

Left

1982

Pharmacotherapy

View full text Add to dashboard Cite

Cefotaxime sodium, a parenteral cephalosporin antibiotic, exerts its bactericidal action through inhibition of bacterial cell wall synthesis. Chemical structure modifications have enabled this compound to be resistant to the action of Richmond I, III, IV, and V beta-lactamase enzymes. Excellent activity against many gram-negative bacilli, especially Enterobacteriaceae, has been demonstrated. Antipseudomonal activity is generally poor, however. Activity against gram-positive cocci, with the notable exception of Streptococcus fecalis, is adequate. Anaerobic activity is variable, particularly against Clostridia and Bacteroides species. Acute, subacute, and chronic toxicity studies in animals were generally unremarkable. No mutagenic effects or reproductive toxicity have been noted in animals. In man, cefotaxime is desacetylated to a microbiologically active metabolite. Urinary excretion is approximately 50-60% and 15-20% of a dose for the parent compound and desacetyl metabolite, respectively. The elimination half-life of cefotaxime is about one hour, with the total body clearance being approximately twice that of the renal clearance. Severe renal dysfunction causes a prolongation of the elimination half-life of cefotaxime and particularly desacetyl cefotaxime. A relatively low degree of protein binding in part attributes to a wide bodily distribution of cefotaxime. Cefotaxime is effective in a variety of infectious processes caused by susceptible organisms. Local reactions at the injection site and hypersensitivity phenomena are the most common adverse effects. Comparative trials attesting to cefotaxime's clinical utility over other parenteral cephalosporins or amino-glycosides are very limited. Based on the available evidence, cefotaxime should be most useful in combating serious gram-negative infections, because of its excellent activity against most of these organisms and its low toxicity profile.

show abstract

Cefotaxime in the treatment of septicaemia and endocarditis

Cited by 8 publications

References 0 publications

Μοξαλακταμη. Μια Νεα Αντιψευδομοναδικη Ευρεως Φασματος Οξυ-Β-Λακταμη. Κλινικη Εργαστηριακη Και Φαρμακοκινητικη Μελετη

Μοξαλακταμη. Μια Νεα Αντιψευδομοναδικη Ευρεως Φασματος Οξυ-Β-Λακταμη. Κλινικη Εργαστηριακη Και Φαρμακοκινητικη Μελετη

The Third-Generation Cephalosporins

Mechanism of Action, Antimicrobial Activity, Pharmacology, Adverse Effects, and Clinical Efficacy of Cefotaxime

Contact Info

Product

Resources

About